Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M M Streng; Marin Bont; Eveline M Delemarre; Rob S Binnendijk; Gaby Smit; Gerco den Hartog; Antonia M W Coppus; Esther de Vries; Michel E Weijerman; Regina Lamberts; Gert de Graaf; Fiona R van der Klis; Gestur Vidarsson; Neele Rave; Louis J Bont; Joanne G Wildenbeest

doi:10.1093/infdis/jiac235

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M M Streng, Marin Bont, Eveline M Delemarre, Rob S Binnendijk, Gaby Smit, Gerco den Hartog, Antonia M W Coppus, Esther de Vries, Michel E Weijerman, Regina Lamberts, Gert de Graaf, Fiona R van der Klis, Gestur Vidarsson, Neele Rave, Louis J Bont, Joanne G Wildenbeest

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.

CLINICAL TRIALS REGISTRATION: NCT05145348.

Original language	English
Pages (from-to)	673-677
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	226
Issue number	4
DOIs	https://doi.org/10.1093/infdis/jiac235
Publication status	Published - 15 Aug 2022

Keywords

Adult
Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19/prevention & control
COVID-19 Vaccines
Down Syndrome
Humans
Prospective Studies
RNA, Messenger
SARS-CoV-2
Vaccination

Access to Document

10.1093/infdis/jiac235Licence: CC BY-NC-ND

jiac235Final published version, 533 KBLicence: CC BY-NC-ND

Cite this

Streng, B. M. M., Bont, M., Delemarre, E. M., Binnendijk, R. S., Smit, G., den Hartog, G., Coppus, A. M. W., de Vries, E., Weijerman, M. E., Lamberts, R., de Graaf, G., van der Klis, F. R., Vidarsson, G., Rave, N., Bont, L. J., & Wildenbeest, J. G. (2022). Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome. Journal of Infectious Diseases, 226(4), 673-677. https://doi.org/10.1093/infdis/jiac235

@article{2d90d98cc7ba4f3281ea828d4356fb8c,

title = "Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome",

abstract = "UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.CLINICAL TRIALS REGISTRATION: NCT05145348.",

keywords = "Adult, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Down Syndrome, Humans, Prospective Studies, RNA, Messenger, SARS-CoV-2, Vaccination",

author = "Streng, {Bianca M M} and Marin Bont and Delemarre, {Eveline M} and Binnendijk, {Rob S} and Gaby Smit and {den Hartog}, Gerco and Coppus, {Antonia M W} and {de Vries}, Esther and Weijerman, {Michel E} and Regina Lamberts and {de Graaf}, Gert and {van der Klis}, {Fiona R} and Gestur Vidarsson and Neele Rave and Bont, {Louis J} and Wildenbeest, {Joanne G}",

note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2022",

month = aug,

day = "15",

doi = "10.1093/infdis/jiac235",

language = "English",

volume = "226",

pages = "673--677",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

Streng, BMM, Bont, M, Delemarre, EM, Binnendijk, RS, Smit, G, den Hartog, G, Coppus, AMW, de Vries, E, Weijerman, ME, Lamberts, R, de Graaf, G, van der Klis, FR, Vidarsson, G, Rave, N, Bont, LJ & Wildenbeest, JG 2022, 'Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome', Journal of Infectious Diseases, vol. 226, no. 4, pp. 673-677. https://doi.org/10.1093/infdis/jiac235

TY - JOUR

T1 - Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

AU - Streng, Bianca M M

AU - Bont, Marin

AU - Delemarre, Eveline M

AU - Binnendijk, Rob S

AU - Smit, Gaby

AU - den Hartog, Gerco

AU - Coppus, Antonia M W

AU - de Vries, Esther

AU - Weijerman, Michel E

AU - Lamberts, Regina

AU - de Graaf, Gert

AU - van der Klis, Fiona R

AU - Vidarsson, Gestur

AU - Rave, Neele

AU - Bont, Louis J

AU - Wildenbeest, Joanne G

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2022/8/15

Y1 - 2022/8/15

N2 - UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.CLINICAL TRIALS REGISTRATION: NCT05145348.

AB - UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.CLINICAL TRIALS REGISTRATION: NCT05145348.

KW - Adult

KW - Antibodies, Viral

KW - Antibody Formation

KW - BNT162 Vaccine

KW - COVID-19/prevention & control

KW - COVID-19 Vaccines

KW - Down Syndrome

KW - Humans

KW - Prospective Studies

KW - RNA, Messenger

KW - SARS-CoV-2

KW - Vaccination

U2 - 10.1093/infdis/jiac235

DO - 10.1093/infdis/jiac235

M3 - Article

C2 - 35748853

SN - 0022-1899

VL - 226

SP - 673

EP - 677

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Abstract

Keywords

Access to Document

Fingerprint

Cite this